Quantinno Capital Management LP Invests $1.12 Million in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Quantinno Capital Management LP purchased a new position in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 49,348 shares of the life sciences company's stock, valued at approximately $1,119,000. Quantinno Capital Management LP owned about 0.06% of Integra LifeSciences at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Quadrant Capital Group LLC boosted its holdings in Integra LifeSciences by 5,960.9% in the fourth quarter. Quadrant Capital Group LLC now owns 1,394 shares of the life sciences company's stock valued at $32,000 after acquiring an additional 1,371 shares during the last quarter. Sterling Capital Management LLC boosted its holdings in Integra LifeSciences by 821.7% in the fourth quarter. Sterling Capital Management LLC now owns 2,166 shares of the life sciences company's stock valued at $49,000 after acquiring an additional 1,931 shares during the last quarter. Nisa Investment Advisors LLC boosted its holdings in Integra LifeSciences by 599.6% in the fourth quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company's stock valued at $74,000 after acquiring an additional 2,800 shares during the last quarter. Covestor Ltd boosted its holdings in Integra LifeSciences by 61.8% in the fourth quarter. Covestor Ltd now owns 5,423 shares of the life sciences company's stock valued at $123,000 after acquiring an additional 2,071 shares during the last quarter. Finally, Empowered Funds LLC bought a new stake in Integra LifeSciences in the fourth quarter valued at approximately $180,000. 84.78% of the stock is currently owned by institutional investors.

Integra LifeSciences Price Performance

Shares of NASDAQ:IART opened at $12.66 on Friday. The company has a quick ratio of 0.73, a current ratio of 1.20 and a debt-to-equity ratio of 0.79. Integra LifeSciences Holdings Co. has a twelve month low of $11.60 and a twelve month high of $32.66. The stock's 50 day moving average is $17.24 and its 200-day moving average is $21.46. The firm has a market capitalization of $983.83 million, a price-to-earnings ratio of -140.65, a PEG ratio of 0.73 and a beta of 1.27.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last issued its earnings results on Monday, May 5th. The life sciences company reported $0.41 earnings per share for the quarter, missing analysts' consensus estimates of $0.43 by ($0.02). Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The firm had revenue of $382.65 million for the quarter, compared to analyst estimates of $381.17 million. During the same period in the previous year, the company earned $0.55 earnings per share. Integra LifeSciences's revenue for the quarter was up 3.7% compared to the same quarter last year. Sell-side analysts forecast that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

IART has been the topic of several analyst reports. Truist Financial reduced their target price on Integra LifeSciences from $26.00 to $19.00 and set a "hold" rating on the stock in a report on Friday, April 11th. JPMorgan Chase & Co. cut their price target on Integra LifeSciences from $24.00 to $12.00 and set an "underweight" rating on the stock in a report on Tuesday, May 6th. Argus upgraded Integra LifeSciences from a "hold" rating to a "buy" rating in a report on Monday, March 31st. Wells Fargo & Company cut their price target on Integra LifeSciences from $25.00 to $13.00 and set an "equal weight" rating on the stock in a report on Tuesday, May 6th. Finally, JMP Securities cut their price target on Integra LifeSciences from $35.00 to $25.00 and set a "market outperform" rating on the stock in a report on Friday, May 9th. Four analysts have rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $18.63.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.

Want to see what other hedge funds are holding IART? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.